

Webinar on the transposition of Directive 2010/63 on the protection of laboratory animals

From: Magda Chlebus
Director Science Policy
Tel: +32 2 626 25 63/
E-mail: magdachlebus@efpia.org

10 November 2011

To: National associations - RAW members - Pre-clinical Development Committee
Transposition Coalition members

Ref. MCH/CL Let 65.824

Dear Madam/Sir,

We are pleased to invite you to a

**Web information session on the implementation of EU Directive 2010/63 on
the protection of Laboratory animals on December 16th 2011
from 10 to 12 CET**

Since the first webinar in May 2011, a series of expert meetings have taken place with the Commission to discuss interpretation of some grey areas in the Directive. It is important that the outcomes of these discussions are shared with stakeholders and experts from EFPIA member companies and associations involved in EU or national debates about the implementation process.

This webinar will:

- Provide up-to-date information about the implementation process
- Highlight grey areas in the new Directive and potential interpretations

We would like to encourage experts involved in transposition debates from EFPIA member companies and associations to participate to this web event.

Attached you will find the draft programme as well as information for your registration and connection to the session. Should you need further information please do not hesitate to contact Catherine Lecerf by email (catherinelecerf@efpia.org) or by phone at 32 2626 25 58.

Yours sincerely,

Magda Chlebus
Director Science Policy



For on-line registration please use the following link:

<http://webevents.services.reg.meeting-stream.com/20111216efpia>

Please note that registrations will be closed on December 12th.

To join the webinar on December 16th please use the same link as above and fill in the right hand screen part (returning users) with your email address, then click on the login button.

To join the audio part of the webinar please dial in the following number:

+44 (0) 1452 564 540

Pre reading material will be sent to registered participants a few days before the web event.

Draft Programme

Welcome and objectives	Guidance tools and timetable of EU and national debates
Magda CHLEBUS EFPIA	
Q&A	
Main features of Directive 2010/63	Highlights of key new provisions
Thierry DECELLE Sanofi Pasteur	
Q&A	
Interpretation of ambiguous provisions	Project vs procedure, reuse vs continued use, delegation of powers from central to local level, lay summaries, etc.
David REYNOLDS Pfizer	
Gill FLEETWOOD GlaxoSmithKline	Statistical reporting, severity and retrospective reporting of severity, simplified procedures, GM animals
Q&A	
Emerging questions in national debates	Key contentious areas at national level and how these are handled from advocacy perspective - case study: Germany
Thorsten RUPPERT VFA	
Q&A and conclusions	